Remove FDA Approval Remove Hormones Remove Insulin Remove Protein
article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

Ozempic (Semaglutide) Ozempic sales in 2022: $8.713 billion Company/Developer: Novo Nordisk Date of first FDA approval: December 5, 2017 Indications Ozempic is FDA-approved for: Type 2 diabetes Price of Ozempic: $1,029 for 1.5 Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics.

Sales 52
article thumbnail

How will $41 million be used to fight chronic and age-related diseases? 

Drug Discovery World

Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. This platform is applicable across a wide scope of disease indications.

Protein 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Creating Future of MedTech Industry with Artificial Intelligence

Delveinsight

In February 2018, the San Diego-based company was granted a de novo request from FDA for the Banyan Brain Trauma Indicator. The test identifies Ubiquitin and Glial Fibrillary Acidic Protein (GFAP)- 2 brain-specific protein biomarkers- that appear rapidly in the blood of a patient after a brain injury.

Protein 56
article thumbnail

Surrogate Endpoints: How to Choose the Best One for Your Rare Disease Trial

XTalks

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 98